Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

By Jérôme Galon, A. Costes, Fátima Sánchez-Cabo, A. Kirilovsky, Bernhard Mlecnik, C. Lagorce-Pagès, M. Tosolini, M. Camus, A. Berger, P. Wind and 6 more. Science, 2006

6,362 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/a40eb85d3f5ca1c2e6b45e9ab9397ab56d9672b7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. A. Mantovani
2. M. Karin
3. Guido Kroemer
4. M. Smyth
5. Lieping Chen
6. L. Zitvogel
7. A. Sica
8. P. Allavena

In Oncology

1. M. Karin
2. A. Mantovani
3. Lieping Chen
4. J. Wolchok
5. Guido Kroemer
6. S. Grivennikov
7. M. Smyth
8. D. Pardoll

Citations in the corpus

• Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma (2016, background): “In CRC particularly, immune infiltration has been demonstrated to have prognostic relevance (Galon et al., 2006; Ogino et al., 2009), but the antigenic determinants of this response have not been elucidated.”
• Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression (2016, background): “For instance, it has been shown that T-cell infiltration correlates with favorable outcome in colorectal [2, 3] and many other cancers [4] and with poor outcome in clear-cell renal cell carcinoma [5].”
• The Consensus Molecular Subtypes of Colorectal Cancer (2015, methodology): “is supported by grants from the Dutch Cancer Society (UVA2011-4969, UVA2014-7245), Worldwide Cancer Research (14-1164), the Maag Lever Darm Stichting (MLDS-CDG 14-03) and the European Research Council (ERG-StG 638193).”
• Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration (2012, background): “’ [25] Objectives ’The purpose of this study was to determine whether CpG island hypermethylation in the promoter region of the APC gene occurs in primary esophageal carcinomas and premalignant lesions, whether freely circulating hypermethylated APC DNA is detectable in the plasma of these patients,”
• Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. (2011, methodology): “org Cancer Res; 71(4) February 15, 2011 1267”
• Transforming Grown Factor-β Signaling in Immunity and Cancer (2019, positive): “T cell exclusion is associated with adverse outcome in colorectal cancer patients (Galon et al., 2006).”
• Artificial intelligence in histopathology: enhancing cancer research and clinical oncology (2022, background): “Histopathology image data harbor prognostically important information such as lymphocyte count 45,46 , chromatin patterns 47”
• Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. (2009, background): “38 (4) Both blocking indoleamine 2,3-dioxygenase39 and adjuvant IL-7 treatment40 result in improved antitumor immunity, which is associated with marked CD8 T-cell activation and Th17 cell enhancement.”
• The Immunological Synapse (2014, background): “The classical tumor-infiltrating lymphocyte (TIL) is a CD8 CTL that can directly kill tumor cells, and the infiltration of tumors by CD8 T cells correlates with better outcome for some tumors (2).”
• LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. (2016, positive): “In contrast, high levels of tumor-infiltrating T cells predict a favorable prognosis in patients with melanoma and other types of cancer (Bogunovic et al., 2009; Galon et al., 2006).”
• Immune escape mechanisms as a guide for cancer immunotherapy (2014, background): “Moreover, examination of the type, density and location of leukocytes infiltrating tumor tissues has been shown to correlate as a better predictor of survival than histopathologic methods in patients with stage I to stage IV colorectal carcinoma (39).”